Risk for specific hematologic cancers down with GLP-1 receptor agonist use in type 2 diabetes

Risk for specific hematologic cancers down with GLP-1 receptor agonist use in type 2 diabetes

Source: Medical Xpress

For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing hematologic cancers compared with insulin and metformin use, according to a research letter published online March 6 in JAMA Network Open.

This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
For patients with type 2 diabetes (T2D), glucagon-like peptide-1 rece… [2100 chars]

Read more